Cite

HARVARD Citation

    Othus, M. et al. (2023). Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG. Leukemia & lymphoma. 64 (1), pp. 250-252. [Online]. 
  
Back to record